[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 58, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 881092, "exercisedValue": 0, "unexercisedValue": 12515}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 51, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 843233, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 53, "title": "CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 621017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 57, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wan-Jen  Hong M.D.", "age": 45, "title": "Senior Vice President of Clinical Development", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.945, "open": 0.93, "dayLow": 0.8221, "dayHigh": 0.93, "regularMarketPreviousClose": 0.945, "regularMarketOpen": 0.93, "regularMarketDayLow": 0.8221, "regularMarketDayHigh": 0.93, "payoutRatio": 0.0, "forwardPE": -0.57615894, "volume": 80371, "regularMarketVolume": 80371, "averageVolume": 162093, "averageVolume10days": 116820, "averageDailyVolume10Day": 116820, "bid": 0.8289, "ask": 0.8845, "bidSize": 1, "askSize": 1, "marketCap": 49120636, "fiftyTwoWeekLow": 0.61, "fiftyTwoWeekHigh": 5.945, "priceToSalesTrailing12Months": 7.017234, "fiftyDayAverage": 0.87822, "twoHundredDayAverage": 0.934115, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -6061937, "profitMargins": 0.0, "floatShares": 18173004, "sharesOutstanding": 43610200, "sharesShort": 594635, "sharesShortPriorMonth": 545657, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0105, "heldPercentInsiders": 0.11343, "heldPercentInstitutions": 0.6235, "shortRatio": 4.85, "shortPercentOfFloat": 0.0806, "impliedSharesOutstanding": 56460500, "bookValue": 1.34, "priceToBook": 0.6492537, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -124318000, "trailingEps": -1.64, "forwardEps": -1.51, "enterpriseToRevenue": -0.866, "enterpriseToEbitda": 0.045, "52WeekChange": -0.85178876, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 0.87, "targetHighPrice": 5.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.75, "targetMedianPrice": 4.5, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 73216000, "totalCashPerShare": 1.294, "ebitda": -133243000, "totalDebt": 17917000, "quickRatio": 3.502, "currentRatio": 3.677, "totalRevenue": 7000000, "debtToEquity": 23.625, "revenuePerShare": 0.124, "returnOnAssets": -0.49751, "returnOnEquity": -0.96328, "grossProfits": 7000000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -19.28671, "financialCurrency": "USD", "symbol": "PRLD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1755288603, "regularMarketTime": 1755288001, "exchange": "NMS", "messageBoardId": "finmb_373775974", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -7.93651, "regularMarketPrice": 0.87, "marketState": "CLOSED", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601040600000, "postMarketChangePercent": 0.0, "postMarketPrice": 0.87, "postMarketChange": 0.0, "regularMarketChange": -0.075, "regularMarketDayRange": "0.8221 - 0.93", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 162093, "fiftyTwoWeekLowChange": 0.26, "fiftyTwoWeekLowChangePercent": 0.42622948, "fiftyTwoWeekRange": "0.61 - 5.945", "fiftyTwoWeekHighChange": -5.0750003, "fiftyTwoWeekHighChangePercent": -0.85365856, "fiftyTwoWeekChangePercent": -85.17888, "earningsTimestamp": 1755174600, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.64, "epsForward": -1.51, "epsCurrentYear": -1.07, "priceEpsCurrentYear": -0.81308407, "fiftyDayAverageChange": -0.008220017, "fiftyDayAverageChangePercent": -0.009359861, "twoHundredDayAverageChange": -0.06411499, "twoHundredDayAverageChangePercent": -0.06863715, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-25", "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]